NasdaqGS - Nasdaq Real Time Price ? USD Dynavax Technologies Corporation (DVAX) Follow Compare 11.79 +0.01 (+0.08%) At close: November 4 at 4:00 PM EST 11.63 -0.16 (-1.36%) After hours: November 4 at 6:38 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors Gamco Investors lowers stake in media firm Paramount Global. Deep Track Capital increases stake in biopharmaceutical firm Dynavax. Barrons.com ? 3 days ago COMB.BR JANX TPNTF Dynavax Adopts Limited-Duration Stockholder Rights Plan Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). PR Newswire ? 6 days ago DVAX +0.08% Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. PR Newswire ? 11 days ago DVAX +0.08% High Growth Tech Stocks In The United States With Promising Potential Over the last 7 days, the United States market has remained flat, yet it has experienced a robust 38% increase over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks with promising potential involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. Simply Wall St. ? 13 days ago DVAX +0.08% TRIP WDC State Street Corp's Strategic Reduction in Dynavax Technologies Holdings On September 30, 2024, State Street Corp executed a significant transaction involving the shares of Dynavax Technologies Corp (NASDAQ:DVAX), a prominent player in the biopharmaceutical sector. Despite the reduction, State Street Corp maintains a substantial position in DVAX, reflecting a 5.90% ownership in the company. State Street Corp, headquartered at One Lincoln Street, Boston, MA, is a global leader in investment management. GuruFocus.com ? 19 days ago DVAX +0.08% STT Dynavax Technologies Corp (DVAX) Q2 2024 Earnings Call Highlights: Record HEPLISAV-B Sales and ... Dynavax Technologies Corp (DVAX) reports a 24% increase in HEPLISAV-B revenue and advances its vaccine pipeline, while navigating rising expenses and market uncertainties. GuruFocus.com ? 26 days ago DVAX +0.08% Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains? Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 27 days ago DVAX +0.08% Lennar, Bitdeer, and More Stocks See Action From Activist Investors Deep Track Capital has switched an activist stance in biopharmaceutical firm Dynavax. Tether Holdings increased a stake in agricultural firm Adecoagro. Barrons.com ? last month LEN-B JANX AGRO Federated Hermes, Inc. Reduces Stake in Dynavax Technologies Corp On August 31, 2024, Federated Hermes, Inc., a prominent investment firm, executed a significant transaction involving the shares of Dynavax Technologies Corp (NASDAQ:DVAX). Following this transaction, the firm's position in DVAX now accounts for 4.70% of their total holdings, marking a strategic shift in their investment approach. Federated Hermes, Inc., headquartered at 1001 Liberty Avenue, Pittsburgh, PA, is a key player in the investment sector, managing an equity portfolio worth $42.19 billion. GuruFocus.com ? last month DVAX +0.08% FHI High Growth Tech Stocks In The United States To Watch Over the last 7 days, the market has dropped 3.4%, but it has risen by 20% in the last year with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors looking to maximize their returns. Simply Wall St. ? last month ENFN DVAX +0.08% XOMA Lantheus Appoints Julie Eastland as New Board Member BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus’ Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a membe GlobeNewswire ? last month LNTH DVAX +0.08% How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98% The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Zacks ? 2 months ago DVAX +0.08% Dynavax Technologies Corporation Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next The quarterly results for Dynavax Technologies Corporation ( NASDAQ:DVAX ) were released last week, making it a good... Simply Wall St. ? 2 months ago DVAX +0.08% Dynavax Technologies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Dynavax Technologies ( NASDAQ:DVAX ) Second Quarter 2024 Results Key Financial Results Revenue: US$73.8m (up 23% from... Simply Wall St. ? 2 months ago DVAX +0.08% Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript DVAX earnings call for the period ending June 30, 2024. Motley Fool ? 2 months ago DVAX +0.08% Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 33.33% and 4.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago DVAX +0.08% Dynavax Technologies: Q2 Earnings Snapshot EMERYVILLE, Calif. AP) — Dynavax Technologies Corp. DVAX) on Tuesday reported second-quarter earnings of $11.4 million. Associated Press Finance ? 2 months ago DVAX +0.08% Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2024. PR Newswire ? 2 months ago DVAX +0.08% Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close. PR Newswire ? 3 months ago DVAX +0.08% Dynavax doses first subject in Phase I/II shingles vaccine trial The trial will assess the safety, tolerability, and immunogenicity of Z-1018 compared to the existing shingles vaccine, Shingrix. Clinical Trials Arena ? 4 months ago DVAX +0.08% Performance Overview Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return DVAX S&P 500 YTD -15.67% +19.77% 1-Year -17.09% +31.07% 3-Year -43.70% +22.57%
